A Veracyte employee works on a computer in a Veracyte lab with her colleagues. A Veracyte employee works on a computer in a Veracyte lab with her colleagues.

Who we are

About Veracyte

Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. We collaborate closely with physicians and researchers to identify unmet needs that stand in the way of better care. And then, we find the answers.

Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and treatment decisions for challenging diseases. These include thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment.

Our tests are available in the US through our central laboratories. We are also making our tests accessible to patients worldwide through other laboratories that can perform them locally.

 

Our vision

To transform cancer care for patients all over the world

 

Our promise

To empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer

400K

Our tests have benefited over 400,000 patients.1

>7M

We address tests in cancers that affect 7 million people worldwide.2-4

See our corporate presentation

Read our latest corporate presentation to learn more about our strategy, results and more.

Corporate presentation

Our principles

Veracyte has a well-established framework for identifying unmet clinical needs, developing tests to effectively address them, and making them widely available to patients. Central to this framework are our guiding principles, which drive our unwavering commitment to delivering exceptional diagnostics.

Icon of two people, representing “innovate collaboratively” principle

Innovate collaboratively

We collaborate with clinicians and scientists to identify unmet needs and develop solutions that make clinicians’ lives easier and improve outcomes for patients.

Icon of a magnifying glass, representing “better data, better insights” principle

Better data, better insights

We use genomics, machine learning and other technologies in our exhaustive pursuit of data. This process enables us to deliver actionable insights rooted in both the known and the novel.

Icon of a graph line going up, representing “rigorously raise the bar” principle

Rigorously raise the bar

We take pride in ensuring product performance and utility. For each test, we build robust evidence across a broad range of clinical studies, because clinicians and patients need high-quality, reliable results they can trust.

Icon of a globe, representing “enable global access

Enable global access

We make our tests widely available to patients worldwide through our flexible business model and proven ability to develop tests that clinicians will use and that health plans will pay for.

Headshot of Marc Stapley, Chief Executive Officer
Headshot of Rebecca Chambers, Chief Financial Officer

Meet our leadership team

Leadership

REFERENCES

  1. Data on file. 

  2. Cancer. World Health Organization. Published February 3, 2022. Accessed July 19, 2023. https://www.who.int/news-room/fact-sheets/detail/cancer

  3. Thyroid Cancer – Statistics. Cancer.Net. Accessed July 19, 2023. https://www.cancer.net/cancer-types/thyroid-cancer/statistics

  4. Bladder Cancer. International Agency for Research on Cancer. Accessed July 19, 2023. https://www.iarc.who.int/cancer-type/bladder-cancer/